This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-09 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Albany is in the central part of Oregon's most populated region, the Willamette Valley. The city rests along the confluence of the Calapooia and Willamette rivers, and although most of Albany falls within Linn County, a smaller portion of the city rests to the north of its downtown on the west bank of the Willamette River in Benton County. According to the United States Census Bureau, the city has a total area of 17.75 square miles (45.97 km2), of which 17.54 square miles (45.43 km2) is land and 0.21 square miles (0.54 km2) is water. Albany has 21.7 square miles (56 km2) within its urban growth boundary. Throughout the city limits and urban growth area, there are limited hills; the city is one of the lowest points along the Willamette Valley, with elevations ranging 180 to 430 feet (55 to 131 m) above sea level. The North Albany district has the most variable elevation, while the downtown and southern end of town have little elevation change throughout.
=== First trial === The case attracted nationwide publicity in the United States. The trial began in February 1982. Evidence presented by the prosecution consisted of circumstantial evidence, imputation of financial motive, extensive testimony by various maids, including Maria Schrallhammer who was a prominent witness at both trials, chauffeurs, doctors, and personal exercise trainers, a black bag with drugs, and a used syringe, reported to contain traces of insulin, found in Claus von Bülow's mansion. There was much evidence of excessive use of sedatives, vitamins, and other drugs by her, including testimony of alcohol and substance abuse problems. Harvard endocrinologist George Cahill testified that he was convinced that her brain damage was the result of injected insulin. Claus von Bülow was convicted.
Steroid hormones are transported through the blood by being bound to carrier proteins—serum proteins that bind them and increase the hormones' solubility in water. Some examples are sex hormone-binding globulin (SHBG), corticosteroid-binding globulin, and albumin. Most studies say that hormones can only affect cells when they are not bound by serum proteins. In order to be active, steroid hormones must free themselves from their blood-solubilizing proteins and either bind to extracellular receptors, or passively cross the cell membrane and bind to nuclear receptors. This idea is known as the free hormone hypothesis. This idea is shown in Figure 1 to the right.
==== Combination formulations ==== Adapalene/benzoyl peroxide (CD-0271/CD-1579; Epiduo; GK-530G; Tactuo; TactuPump) – combination of adapalene (retinoid) and benzoyl peroxide (undefined mechanism of action) Adapalene/benzoyl peroxide/clindamycin phosphate (Cabtreo; IDP-126) – combination of adapalene (retinoid), benzoyl peroxide (undefined mechanism of action), and clindamycin phosphate (lincosamide antibiotic) Benzoyl peroxide/clindamycin (Duac) – combination of benzoyl peroxide (undefined mechanism of action) and clindamycin (lincosamide antibiotic) Benzoyl peroxide/clindamycin low dose (Acanya; BenzaClin; Clin-BPO; Onexton) – combination of benzoyl peroxide (undefined mechanism of action) and clindamycin (lincosamide antibiotic) Benzoyl peroxide/tretinoin – combination of benzoyl peroxide (undefined mechanism of action) and tretinoin (retinoid) Clindamycin/tretinoin (Acnatac; Acnex; CLin-RA; Ziana) – combination of clindamycin (lincosamide antibiotic) and tretinoin (retinoid) Ethinylestradiol/drospirenone low-dose (Yasmin, Yaz) – combination of ethinylestradiol (estrogen) and drospirenone (progestogen) and a combined oral contraceptive Ethinylestradiol/drospirenone/levomefolic acid (BAY98-7071; Beyaz; Safyral; Yasmin Plus; Yaz Flex Plus; Yaz Plus) – combination of ethinylestradiol (estrogen), drospirenone (progestogen), and levomefolic acid (vitamin B9) and a combined oral contraceptive
Sources: en.wikipedia.org
At the biochemical level, YAP is part of and regulated by the Hippo signaling pathway where a kinase cascade results in its “inactivation”, along with that of TAZ. In this signaling cascade, TAO kinases phosphorylate Ste20-like kinases, MST1/2, at their activation loops (Thr183 for MST1 and Thr180 for MST2). Active MST1/2 then phosphorylate SAV1 and MOB1A/B which are scaffold proteins that assist in the recruitment and phosphorylation of LATS1/2. LATS1/2 can also be phosphorylated by two groups of MAP4Ks. LATS1/2 then phosphorylate YAP and TAZ which causes them to bind with 14-3-3, resulting in cytoplasmic sequestration of YAP and TAZ. The result of the activation of this pathway is the restriction of YAP/TAZ from entering the cell nucleus. Once inside the nucleus, physical association of YAP with binding partners such as beta-catenin mediates the recruitment of SWI/SNF complexes, which in turn generate DNA accessibility needed to activate enhancers.
==== Gangrene and gallbladder rupture ==== Cholecystitis causes the gallbladder to become distended and firm. Distension can lead to decreased blood flow to the gallbladder, causing tissue death and eventually gangrene. Once tissue has died, the gallbladder is at greatly increased risk of rupture (perforation), which can cause sharp pain. Rupture can also occur in cases of chronic cholecystitis. Rupture is a rare but serious complication that leads to abscess formation or peritonitis. Massive rupture of the gallbladder has a mortality rate of 30%.
=== Phosphite triester synthesis === In the 1970s, substantially more reactive P(III) derivatives of nucleosides, 3'-O-chlorophosphites, were successfully used for the formation of internucleosidic linkages. This led to the discovery of the phosphite triester methodology. The group led by M. Caruthers took the advantage of less aggressive and more selective 1H-tetrazolidophosphites and implemented the method on solid phase. Very shortly after, the workers from the same group further improved the method by using more stable nucleoside phosphoramidites as building blocks. The use of 2-cyanoethyl phosphite-protecting group in place of a less user-friendly methyl group led to the nucleoside phosphoramidites currently used in oligonucleotide synthesis (see Phosphoramidite building blocks below). Many later improvements to the manufacturing of building blocks, oligonucleotide synthesizers, and synthetic protocols made the phosphoramidite chemistry a very reliable and expedient method of choice for the preparation of synthetic oligonucleotides.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.